BR0005765A - Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas - Google Patents

Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas

Info

Publication number
BR0005765A
BR0005765A BR0005765-7A BR0005765A BR0005765A BR 0005765 A BR0005765 A BR 0005765A BR 0005765 A BR0005765 A BR 0005765A BR 0005765 A BR0005765 A BR 0005765A
Authority
BR
Brazil
Prior art keywords
treatment
diabetic
aldose reductase
combination
prodrug
Prior art date
Application number
BR0005765-7A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0005765A publication Critical patent/BR0005765A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Patente de Invenção: <B>"COMBINAçãO DE INIBIDORES DE ALDOSE REDUTASE E AGENTES ANTI-HIPERTENSIVOS PARA O TRATAMENTO DE COMPLICAçõES DIABéTICAS"<D>. Esta invenção é dirigida a métodos, composições farmacêuticas e kits compreendendo um inibidor de aldose redutase (ARI), uma sua pró-droga, ou um sal farmaceuticamente aceitável do referido ARI ou da referida pró-droga; um agente anti-hipertensivo, uma sua pró-droga, ou um sal farmaceuticamente aceitável do referido agente anti-hipertensivo ou da referida pró-droga. Esta invenção ainda se dirige a métodos que utilizam essas composições farmacêuticas para o tratamento de complicações diabéticas tais como a neuropatia diabética, nefropatia diabética, retinopatia diabética, enfarte de miocárdio, cataratas e cardiomiopatia diabética.
BR0005765-7A 1999-12-07 2000-12-07 Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas BR0005765A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16938099P 1999-12-07 1999-12-07

Publications (1)

Publication Number Publication Date
BR0005765A true BR0005765A (pt) 2001-07-17

Family

ID=22615435

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0005765-7A BR0005765A (pt) 1999-12-07 2000-12-07 Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas

Country Status (5)

Country Link
US (2) US20020068740A1 (pt)
EP (1) EP1106210A3 (pt)
JP (1) JP2001163805A (pt)
BR (1) BR0005765A (pt)
CA (1) CA2327575A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
KR20040014600A (ko) * 2001-07-02 2004-02-14 산텐 세이야꾸 가부시키가이샤 알파1 수용체 차단약을 유효 성분으로 하는 시신경 보호제
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2831446B1 (fr) 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
ATE352312T1 (de) * 2001-12-29 2007-02-15 Novo Nordisk As Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
KR20110134952A (ko) * 2002-06-27 2011-12-15 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
US20050261355A1 (en) * 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
JP2007015924A (ja) * 2003-06-12 2007-01-25 Sanwa Kagaku Kenkyusho Co Ltd 抗癌剤耐性を克服する薬剤及びそのスクリーニング方法
WO2005037284A1 (en) * 2003-10-15 2005-04-28 Pfizer Products Inc. Sorbitol dehydrogenase inhibitor and hypertensive agent combinations
US7750036B2 (en) * 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
WO2005051322A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
JP4014053B2 (ja) 2004-01-30 2007-11-28 株式会社三和化学研究所 糖尿病黄斑症の予防又は治療剤
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20080096923A1 (en) * 2004-07-23 2008-04-24 Aniz Girach Methods For Diagnosing And Treating Diabetic Microvascular Complications
WO2006063048A2 (en) 2004-12-06 2006-06-15 Avigen, Inc. Ibudilast for treating neuropathic pain and associated syndromes
US7832364B2 (en) * 2006-12-14 2010-11-16 Texaco Inc. Heat transfer unit for steam generation and gas preheating
US20080181876A1 (en) * 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
EA018600B1 (ru) * 2008-07-25 2013-09-30 Бионевия Фармасьютикалс, Инк. Новые кристаллические соли эпалрестата
EA016904B1 (ru) 2008-09-06 2012-08-30 Бионевия Фармасьютикалс, Инк. Новый холиновый сокристалл эпалрестата
NZ594738A (en) 2009-01-23 2013-11-29 Hanmi Science Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
WO2012100208A1 (en) 2011-01-20 2012-07-26 Bionevia Pharmaceuticals Inc. Modified release compositions of epalrestat or a derivative thereof and methods for using the same
US9308165B2 (en) 2013-08-22 2016-04-12 Therapeutic Vision, Inc. Composition for treating ocular effects of diabetes
BR112020001755A2 (pt) * 2017-07-28 2020-07-21 Applied Therapeutics Inc. composições e métodos para o tratamento de galactosemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
IL124236A (en) * 1997-05-05 2003-01-12 Pfizer Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor

Also Published As

Publication number Publication date
US20030050301A1 (en) 2003-03-13
US20020068740A1 (en) 2002-06-06
EP1106210A3 (en) 2003-12-03
EP1106210A2 (en) 2001-06-13
JP2001163805A (ja) 2001-06-19
CA2327575A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
MA30765B1 (fr) Derives innovants du thiophene
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
BR9811585A (pt) Agonistas de vasopressinas tricìclicas
HUP0004318A2 (hu) Atorvastatint és egy vérnyomáscsökkentő szert tartalmazó gyógyszerkészítmény
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
MA27556A1 (fr) Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
MA29568B1 (fr) Composes d&#39;azaindazole et methodes d&#39;utilisation desdits composes
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
GT199700009AA (es) Terapia combinada para la osteoporosis
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
BR9810520A (pt) Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial
PT1115701E (pt) Ureias de arilsulfonanilida
MA26965A1 (fr) Association d&#39;agonistes de gaba et d&#39;inhibiteurs d&#39;aldose-reductase.
BR9813699A (pt) Combinação eficaz para o tratamento da impotência
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
EP1064964A3 (en) Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications
BR9809848A (pt) Composição
EP1106184A3 (en) Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1925 DE 27/11/2007.